Mineralys Therapeutics (MLYS) Stock Dropped, So What Is Driving Attention Now?

Mineralys Therapeutics (MLYS) recently presented new analyses from its pivotal Phase 3 Launch-HTN and Phase 2 Explore-OSA trials for lorundrostat, highlighting clinically meaningful blood pressure reductions in patients with uncontrolled hypertension and related comorbidities.

Mineralys Therapeutics has been under pressure despite the fresh lorundrostat data, with the share price falling 27.55% over the past 30 days and 43.15% year to date, while the 1 year total shareholder return is down 53.40% but the 3 year total shareholder return remains strongly positive at 142.82%. This indicates that long term holders have still seen substantial gains even as recent momentum has faded.

Scan for other health-focused stories like Mineralys Therapeutics by checking our hand picked 33 healthcare AI stocks that could be shaping the next wave of treatment breakthroughs.

Bulls point to Mineralys Therapeutics’ late stage lorundrostat data and long term share gains. Bears focus on steep recent declines and ongoing losses. Which side does the current valuation lean toward next?

Most Popular Narrative: 58% Undervalued

Analysts following Mineralys Therapeutics see a large gap between the last close at $20.30 and their narrative fair value of $48.50. This frames today’s slide as more than just short term noise.

Progress toward an NDA filing for lorundrostat in uncontrolled and resistant hypertension, supported by multiple Phase III and proof of concept trials, positions the company to potentially transition from a pure R&D story toward a revenue generating profile. This could materially affect future revenue and earnings visibility.

See why 4 investors see Mineralys Therapeutics as 58% undervalued.

Result: Fair Value of $48.50 (UNDERVALUED)

Still, the story can flip quickly if lorundrostat hits regulatory hurdles or if class competition and ongoing losses keep pressure on Mineralys Therapeutics’ path to profitability.

Find out about the key risks to this Mineralys Therapeutics narrative.

Next Steps

Sentiment on Mineralys Therapeutics is split, so move quickly. Review the underlying numbers and form your own stance using the full picture in the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Mineralys Therapeutics?

If you stop with Mineralys Therapeutics, you risk missing other opportunities. Use the Simply Wall Street Screener to surface fresh ideas tailored to your style.

• Target resilient cash generators by scanning companies with healthy finances and durable balance sheets using our list of solid balance sheet and fundamentals (25 results).
• Hunt for mispriced opportunities that combine quality fundamentals with attractive entry points through the 33 high quality undervalued stocks.
• Zero in on under-the-radar prospects with strong numbers and limited coverage by reviewing the 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com